✦ LIBER ✦

Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

✍ Scribed by Brigitte A.B. Essers; Shanley C. Seferina; Vivianne C.G. Tjan-Heijnen; Johan L. Severens; Annoesjka Novák; Marjolein Pompen; Ulrich H. Oron; Manuela A. Joore

Book ID: 109079133
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 157 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2009.00683.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An Economic Evaluation of Adjuvant Trast

An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer

✍ Wen Chen; Zefei Jiang; Zhimin Shao; Qiang Sun; Kunwei Shen 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

A pilot study of adjuvant nanoparticle a

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

✍ Denise Yardley; Howard Burris; Nancy Peacock; Eric Raefsky; Marianne Melnik; Rog 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 171 KB

Evaluation of HER2 status: For the treat

Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)

✍ Shinobu Umemura; Goi Sakamoto; Hironobu Sasano; Hitoshi Tsuda; Futoshi Akiyama; 📂 Article 📅 2001 🏛 Springer Japan 🌐 English ⚖ 998 KB

Implementation of trastuzumab in conjunc

Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands

✍ L. de Munck; M. Schaapveld; S. Siesling; J. Wesseling; A. C. Voogd; V. C. G. Tja 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 192 KB

The Cost-Utility of Sequential Adjuvant

The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial

✍ Chris Skedgel; Daniel Rayson; Tallal Younis 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB